ClinicalTrials.gg
RecruitingNCT06174610Updated Jun 3, 2025

Changes of Renal Resistive Index in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.

An observational study in Acute Kidney Injury, sponsored by Uniwersytecki Szpital Kliniczny w Opolu. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Uniwersytecki Szpital Kliniczny w Opolu · Observational

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 25 studies in Acute Kidney Injury with a site in Poland — 5 open to participants now, 5 under way, none of them phase 3. Acute Kidney Injury · Poland.

Planned enrollment
10th of 14
50 · median 82
Started
2023
with 2 others
Observational
14 of 25
3 open now
Registered
20th of 25
by date
Lead sponsor
3 of 25
Uniwersytecki Szpital Kliniczny w Opolu

Among the 25 studies in Acute Kidney Injury with a site in Poland, this one is the 10th largest by planned enrollment of the 14 observational ones that give a count, is one of 3 that started in 2023, is one of 14 observational ones, and was the 20th registered.

Acute Kidney Injury

1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

5 of the 25 studies in Acute Kidney Injury with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 229 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Acute Kidney Injury with a site in Poland, or all of them as a file.
02

Study summary

The aim of the study is to determine whether there is a correlation between changes in the renal resistive index and the restoration of kidney function in critically ill patients undergoing continuous renal replacement therapy.

Read the detailed description

A significant number of critically ill patients experience acute kidney injury (AKI), an independent factor contributing to increased mortality. Prevention of AKI and monitoring kidney function are crucial. Commonly used markers such as serum creatinine and hourly diuresis are employed to assess AKI severity, but they are not ideal due to their late elevation in the disease course. Therefore, alternative methods for detecting and evaluating kidney dysfunction at an earlier stage are sought.

Previous studies have demonstrated a correlation between the risk of AKI and the resistive index of renal parenchymal arteries. Renal resistive index (RRI) is a parameter calculated from Doppler measurements, representing the difference between peak blood velocity during systole and end-diastolic velocity divided by peak systolic velocity [(Vs-Vd) /Vs]. In healthy adult kidneys, the RI typically ranges from 0.6 to 0.7. Changes in RRI can be observed much earlier than an increase in serum creatinine concentration and/or a decrease in hourly diuresis.

Some patients with acute kidney injury require renal replacement therapy. Continuous renal replacement therapy (CRRT) is commonly used in critically ill patients, causing less circulatory destabilization compared to intermittent therapies. However, adverse effects accompany renal replacement therapies, including thromboembolic complications, bleeding, infections, blood cell damage, altered drug pharmacokinetics, and loss of proteins and vitamins.

In addition to determining the appropriate initiation time for CRRT, identifying the optimal moment to end the treatment is crucial. CRRT is typically applied for several days, and during the procedure, it is challenging to ascertain whether renal function has improved and whether CRRT can be safely discontinued. The hypothesis is that there may be a correlation between changes in RRI and the recovery of kidney function. This may enable the early identification of patients who have regained kidney function, allowing for the earlier termination of CRRT.

In 1989, a study was conducted on children undergoing peritoneal dialysis due to AKI, showing a relationship between a decrease in RRI and the restoration of kidney function. However, no similar study has been conducted on adult patients undergoing continuous renal replacement therapy.

The planned project will be based on daily ultrasonographic examinations, measuring RRI of the arcuate and/or interlobar arteries of both kidneys.

03

Conditions studied

  • Acute Kidney Injury

Browse trials for

Keywords

  • Acute Kidney Injury (AKI)
  • Continous Renal Replacement Therapy (CRRT)
  • Critical Care
  • Renal Resistive Index (RRI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult ICU patients undergoing CRRT due to AKI

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All ICU patients undergoing CRRT due to AKI

Exclusion criteria

Exclusion Criteria:

  • age \<18 years
  • pregnancy
  • history of chronic kidney disease in stage 4 or 5
  • post-kidney transplant status
  • mechanical circulatory support
  • occurrence of one or more conditions preventing reliable RRI measurement in both kidneys:

    • challenging technical conditions of ultrasound examination, hindering proper visualization of the kidney
    • post-kidney injury in grade III and higher, according to AAST
    • advanced parenchymal kidney pathology: atrophy, hypoplasia, cirrhosis, extensive ischemia (more than 2/3 of the parenchyma),
    • kidney diseases preventing parenchyma identification: advanced cancer (stage above T1 according to TNM), certain forms of polycystic kidney disease
    • inflammatory kidney diseases
    • obstructive uropathy
    • renal vascular pathologies: renal vein thrombosis, significant stenosis (>60%), and renal artery occlusion.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Acute Kidney Injury + CRRT

    Critically ill patients admitted to the intensive care unit (ICU), undergoing continuous renal replacement therapy due to Acute Kidney Injury. Diagnostic Test: Daily Doppler measurement of Renal Resistive Index

    Diagnostic Test: Measurement of Renal Resistive Index

Interventions

  • Diagnostic testMeasurement of Renal Resistive Index

    The kidneys are preliminarily visualized in a 2D projection, followed by identifying interlobar or arcuate vessels using color Doppler. Flow measurements in these vessels are performed using pulsed-wave Doppler. Renal Resistive Index is determined over three cardiac cycles (five in the case of atrial fibrillation) in two different arteries, each in a different kidney section. Subsequently, measurements from each artery are averaged. If possible, the examination should be conducted bilaterally. The investigators do not have access to previous measurements (each study is recorded on a separate card).

06

What researchers measure

Primary outcomes

  1. Relationship between changes in RRI and recovery of kidney function

    The first ultrasound examination should be performed before the initiation of CRRT and, if not possible, within 24 hours of starting CRRT. Subsequently, the renal arteries will be assessed once a day during CRRT and after its completion until kidney function improves or there is a need for a return to renal replacement therapy. The return of kidney function is defined as a stable (increase \<0.3 mg/dl/24h) or decreasing serum creatinine level in two consecutive tests conducted at intervals of at least 24 hours and an average hourly diuresis \>0.5 ml/kg over the last 12 hours, with or without loop diuretics.

    Time frame: on average from 1 to 3 weeks

07

Study locations

1 of 1 sites recruiting
  • Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu
    Opole, Opolskie 45-372, Poland
    Recruiting
08

References and documents

Publications

  • Patriquin HB, O'Regan S, Robitaille P, Paltiel H. Hemolytic-uremic syndrome: intrarenal arterial Doppler patterns as a useful guide to therapy. Radiology. 1989 Sep;172(3):625-8. doi: 10.1148/radiology.172.3.2672090. PubMed 2672090 ↗
  • Katulka RJ, Al Saadon A, Sebastianski M, Featherstone R, Vandermeer B, Silver SA, Gibney RTN, Bagshaw SM, Rewa OG. Determining the optimal time for liberation from renal replacement therapy in critically ill patients: a systematic review and meta-analysis (DOnE RRT). Crit Care. 2020 Feb 13;24(1):50. doi: 10.1186/s13054-020-2751-8. PubMed 32054522 ↗
  • Fernandez SN, Santiago MJ, Gonzalez R, Lopez J, Solana MJ, Urbano J, Lopez-Herce J. Changes in hemodynamics, renal blood flow and urine output during continuous renal replacement therapies. Sci Rep. 2020 Nov 27;10(1):20797. doi: 10.1038/s41598-020-77435-x. PubMed 33247145 ↗
  • Fernandez SN, Lopez J, Gonzalez R, Solana MJ, Urbano J, Aguado A, Lancharro A, Lopez-Herce J, Santiago MJ. Doppler ultrasound in the assessment of renal perfusion before and during continuous kidney replacement therapy in the pediatric intensive care unit. Pediatr Nephrol. 2022 Dec;37(12):3205-3213. doi: 10.1007/s00467-022-05428-1. Epub 2022 Mar 14. PubMed 35286455 ↗
  • Ninet S, Schnell D, Dewitte A, Zeni F, Meziani F, Darmon M. Doppler-based renal resistive index for prediction of renal dysfunction reversibility: A systematic review and meta-analysis. J Crit Care. 2015 Jun;30(3):629-35. doi: 10.1016/j.jcrc.2015.02.008. Epub 2015 Feb 24. PubMed 25746587 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for May 2026, 29 months after the start.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 29 months is above that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2023
First posted
Dec 18, 2023
StartActual
Dec 19, 2023
Primary completionEst.
May 21, 2026
CompletionEst.
Dec 18, 2026
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06174610
Lead sponsor
Uniwersytecki Szpital Kliniczny w Opolu
Responsible party
Maciej Piwoda (Principal Investigator, Uniwersytecki Szpital Kliniczny w Opolu) — Principal investigator
First posted
Dec 18, 2023
Start date
Dec 19, 2023
Primary completion
May 21, 2026 (estimated)
Completion
Dec 18, 2026 (estimated)
Last update
Jun 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion